BASAGLAR KWIKPEN

(Insulin glargine)

Approved

AAzienda U.S.L. 1 di Massa e Carrara

BASAGLAR KWIKPEN is one of 19 biologic programs targeting Diabetes Mellitus, Type 2. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Diabetes Mellitus, Type 2Completed

Diabetes Mellitus, Type 2Approved

Completed

Competition

Competitive Landscape

21 competitors in Diabetes Mellitus, Type 2

#DrugCompanyPhaseTrials

Ozempic

Novo Nordisk

Approved

12 2

Farxiga

AstraZeneca

Approved

2 3

Mounjaro

Eli Lilly

Approved

2 4

Trulicity

Eli Lilly

Approved

2 5

Actos

Takeda

Approved

1 6

Jardiance

Boehringer Ingelheim

Approved

4 7

Januvia

ZZydus Therapeutics Inc.

Approved

2 8

Glucophage

EMD Serono

Approved

2 9

Tradjenta

Boehringer Ingelheim

Approved

1 10

Invokana

WWim Janssens

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 3Active, not recruiting

Diabetes Mellitus, Type 1

NCT07076199

Clinical

Trials by Indication[1]

Diabetes Mellitus, Type 22 trials

A Six Month, Open Label, Randomized Parallel Group Trial Assessing The Impact Of Dry Powder Inhaled Insulin (Exubera) On Glycemic Control Compared To Insulin Glargine (Lantus) In Patients With Type 2 Diabetes Mellitus Who Are Poorly Controlled On A Combination Of Two Or More Oral Agents

Completed· Pfizer logo

Pfizer·Approved·NCT00418522·413 enrolled

A Six Month, Open-Label Outpatient, Randomized Parallel Group Trial Assessing The Impact Of Dry Powder Inhaled Insulin (Exubera®) On Glycemic Control Compared To Insulin Glargine (Lantus®) In Patients With Type 2 Diabetes Mellitus Who Are Poorly Controlled On A Combination Of Two Or More Oral Agents

Completed· Pfizer logo

Pfizer·Approved·NCT00391027·261 enrolled

Diabetes Mellitus, Type 11 trial

A 26-week Study Comparing the Efficacy and Safety of Once-weekly Insulin Icodec and Once-daily Insulin Glargine U100, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes

Active, not recruiting· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT07076199·877 enrolled

Diabetes, Type 21 trial

A Study to Evaluate the Efficacy and Safety of Once-weekly Insulin Icodec When Switching From Daily Basal Insulins Compared to Once-daily Insulin Glargine U100 in Adults With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT06340854·412 enrolled

Regulatory

FDA Approval Timeline[4]

Apr 20, 2000

LANTUS SOLOSTAR

BLA BLA021081

Feb 25, 2015

TOUJEO

BLA BLA206538

Dec 16, 2015

BASAGLAR KWIKPEN

BLA BLA205692

Jul 28, 2021

INSULIN GLARGINE

BLA BLA761201

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Insulin glargine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Insulin glargine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Insulin glargine. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (BLA BLA761201). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Azienda U.S.L. 1 di Massa e Carrara company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Approved[1]
Company: AAzienda U.S.L. 1 di Massa e Carrara

BASAGLAR KWIKPEN

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Diabetes Mellitus, Type 22 trials

Diabetes Mellitus, Type 11 trial

Diabetes, Type 21 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News